Transmucosal Absorption Enhancers in the Drug Delivery Field

Edited by
January 2020
406 pages
  • ISBN978-3-03921-848-6 (Paperback)
  • ISBN978-3-03921-849-3 (PDF)

This book is a reprint of the Special Issue Transmucosal Absorption Enhancers in the Drug Delivery Field that was published in

Biology & Life Sciences
Chemistry & Materials Science
Medicine & Pharmacology

Development of strategies to assist the movement of poorly permeable molecules across biological barriers has long been the goal of drug delivery science. In the last three decades, there has been an exponential increase in advanced drug delivery systems that aim to address this issue. However, most proprietary delivery technologies that have progressed to clinical development are based on permeation enhancers (PEs) that have a history of safe use in man. This Special Issue entitled “Transmucosal Absorption Enhancers in the Drug Delivery Field” aims to present the current state-of-the-art in the application of PEs to improve drug absorption. Emphasis is placed on identification of novel permeation enhancers, mechanisms of barrier alteration, physicochemical properties of PEs that contribute to optimal enhancement action, new delivery models to assess PEs, studies assessing safety of PEs, approaches to assist translation of PEs into effective oral, nasal, ocular and vaginal dosage forms and combining PEs with other delivery strategies.

  • Paperback
© 2019 by the authors; CC BY licence
absorption enhancers; sugar-based surfactants; biocompatibility studies; transmucosal drug delivery; intestinal permeation enhancers; sodium cholate (NaC); N-dodecyl-β-D-maltoside (DDM); small intestine; enterocyte; brush border; tryptophan; oral delivery; insulin; GLP-1; intestinal absorption; amino acid; cell-penetrating peptide; combined microsphere; chitosan; cyclodextrin; nasal delivery; nose to brain transport; penetration enhancer; nasal formulation; in vivo studies; nose to brain delivery; antiepileptic drug; drug delivery; block copolymers; thermogel system; chitosan derivatives; amphiphilic polymers; polymeric micelles; quaternization; curcumin; intestinal delivery; mucoadhesiveness; cervicovaginal tumors; cationic functionalization; imatinib; nanocrystals; in situ hydrogel; bioenhancer; cytochrome P450; drug absorption enhancer; efflux; metabolism; P-glycoprotein; pharmacokinetic interaction; tight junction; Aloe vera; gel; whole leaf; absorption enhancement; Caco-2; confocal laser scanning microscopy; F-actin; FITC-dextran; tight junctions; transepithelial electrical resistance; permeation enhancer; oral delivery; formulation; permeability; safety; simulated intestinal fluid; hydrophobization; epithelium; compound 48/80; chitosan; nanoparticles; mast cell activator; vaccine adjuvant; nasal vaccination; absorption enhancer; antimicrobial peptide; Caco-2; claudin; cell-penetrating peptide (CPP); drug delivery; intestinal epithelial cells; KLAL; PN159; tight junction modulator; oral macromolecule delivery; oral peptides; sodium caprate; salcaprozate sodium; epithelial permeability; epithelial transport; nasal permeability; nose-to-brain; simvastatin; nanocapsules; mucoadhesion; CNS disorders; chitosan; nasal; pulmonary; drug administration; absorption enhancers; nanoparticle; and liposome; absorption enhancer; gemini surfactant; intestinal absorption; poorly absorbed drug; Caco-2 cells; PTH 1-34; teriparatide; nasal delivery; pharmacokinetics; osteoporosis; man; sheep; clinical trial; preclinical; Caco-2; intestinal absorption; nanomedicine; nanoparticle; oral delivery; transferrin; ocular drug delivery; cornea; penetration enhancers; ocular conditions; ophthalmology; permeation enhancers; absorption modifying excipients; oral delivery; nasal delivery; ocular delivery; vaginal delivery; transmucosal permeation